Aminologics KRX:074430KOSDAQ
아미노로직스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Aminologics reported revenue of ₩8.2bn, up 73.1% year on year, and operating profit of ₩2.0bn. Aminologics (아미노로직스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Op. margin 20%+ Insider selling Screener
Aminologics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩8.2bn | +73.1% | ₩2.0bn margin 24.1% | ₩990m |
| Q1 2026 | ₩5.4bn | +13.9% | ₩630m margin 11.7% | ₩1.1bn |
| Q4 2025 derived | ₩6.5bn | +62.3% | ₩1.5bn margin 22.4% | −₩258m |
| Q3 2025 | ₩6.0bn | +150.9% | ₩1.4bn margin 23.4% | ₩1.4bn |
| Q2 2025 | ₩4.8bn | -12.4% | ₩216m margin 4.5% | ₩90m |
| Q1 2025 | ₩4.7bn | -4.2% | ₩512m margin 10.8% | ₩2.3bn |
| Q4 2024 derived | ₩4.0bn | -50.5% | −₩391m margin −9.7% | −₩1.8bn |
| Q3 2024 | ₩2.4bn | -42.6% | −₩2.1bn margin −88.9% | −₩1.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Aminologics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Aminologics news Korean headlines
No articles yet.